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ABSTRACT
Background: There are newer diagnostic and therapeutic armamentaria for primary 
lung cancer. Application of molecular genetics in lung cancer management is evolving 
rapidly. However, the traditional knowledge and practices that were applicable before 
the 1980s still hold sway in most developing countries. 
Objective: To highlight the gap in current aetiopathology and management profile of 
primary lung cancers.  
Design: Hospital based prospective study. 
Setting: Metropolitan Lagos University Teaching Hospital which accounts for about 13% 
of Nigerian population. 
Subjects: Two hundread and sixty seven patients referred to our centre with lung 
malignancy as a differential diagnosis.
Results: The research lasted 99 months beginning October 1999 during which 267 
patients were enlisted. There were 148 males (55.4%) and 119 females (44.5%). Stage 
IV patients were 183 (68.5%) while only three patients were found at stage I. Histology 
showed squamous cell carcinoma in 27.7% of cases while adenocarcinoma constituted 
64.0%. Curative surgery was performed for 13.1% while non curative surgery was 
performed for 16.5%.  Correlation between smoking and malignancy was stronger 
among the male than the female patients. 
Conclusion: There is increasing incidence of primary lung cancers among non-smoking 
females. Despite the availability of modern diagnostic and therapeutic tools, the 
developing world is lagging behind in their acquisition and application.
INTRODUCTION
Tumours of the lung are either benign or malignant. 
Malignant tumours are either primary or secondary 
depending on tissue of origin.  Primary malignant 
tumours of the lung are further classified into small 
cell and non small cell tumours of the lung. All 
these variants are available worldwide. While no 
real improvement in the long term survival has 
been obtained in lung cancer, during this decade, a 
significant improvement in cancer control has been 
obtained by biology-driven targeted therapy as with 
anti EGFR tyrosine kinase (1). Two phases can be 
described in the knowledge of lung cancer biology: 
a first phase obtained in the 1980s describing the 
main molecular anomalies and impaired cell control 
mechanisms, and a second phase starting in the 2004-
2005 giving rise to the therapeutic applications of this 
knowledge (1). TP53 somatic mutations are frequent 
in many cancers, and their prognostic and predictive 
values are currently being assessed in clinical trials. 
In fact, TP53 gene therapy is in use in China (2). The 
implications of these are that, somatic mutations have 
followed  different routes to becoming substances of 
clinical application and sequencing several genes  in 
human tumours is on the verge of becoming routine 
clinical practice (2).  An important development 
here is the finding of Paxillin over-expression  that 
occurs during the earliest stages of lung cancer 
development (3).It is therefore being thought of as 
an important screening modality for bronchogenic 
carcinoma  in high risk individuals (3). Smoking is a 
documented risk factor for cancer, especially for lung 
carcinomas. Nicotine and its derived carcinogenic 
nitrosamines contribute to lung cancer development 
and progression through the binding to nicotinic 
acetylcholine receptors (nAchR) in lung cancer 
predisposition. The traditional armamentaria for the 
diagnosis of lung cancers include information from 
history, clinical features, chest radiographs (including 
computerised axial tomographic scan), bronchoscopy 
and cytology/histology amongst others. Beyond 
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these, there is growing interest in the use of tumour 
genetics in clinical practice. Even at that, misdiagnoses 
still occur (5). Hypermethylation of SHOX2 in 
bronchial aspirates appears to be a clinically useful 
tumour marker for identifying subjects with lung 
carcinoma, especially if histological and cytological 
findings after bronchoscopy are ambiguous (6). This 
has the tendency to further strengthen the accuracy 
of diagnosis of bronchogenic carcinoma. Surgery 
for loco-regional control of tumour offers the best 
chance of cure especially at early stages. This can 
be in form of (multi)segmentectomy lobectomy, 
bi-lobectomy and pneumonectomy. This is often 
combined with chemotherapy to mop up subclinical 
metastasis. Radiation therapy offers a lot of support 
for loco-regional palliation. The available therapeutic 
armamentaria notwithstanding, there has been no 
real improvement in the long term survival of lung 
cancers (1). Various tumour markers are now being 
used to monitor the progression of the disease. More 
recently, cytoplasmic HuR expression is known to 
correlate with angiogenesis, lymphangiogenesis and 
poor outcome in lung cancer (7). This promises to offer 
some clinical roles in determining the post-operative 
prognosis of bronchogenic carcinoma in future. 
 Despite these widespread developments and 
applications of molecular genetics in relation to 
tumorigenesis, diagnosis, treatment and monitoring 
of treatment, the traditional knowledge and practices 
that were applicable before the 1980s still hold sway 
in most places in Africa. There is therefore a wide gap 
between what is obtainable in most parts of Africa 
and the developed world.
 This research was conducted to highlight the 
staggering gap in the current aetiopathological and 
management profile of lung cancer. It is also an 
assessment of the readiness of the developing world 
for the challenges of lung cancer management as we 
enter the new decade.  
 
MATERIALS AND METHODS
The research took place at the Lagos University 
Teaching Hospital, Lagos Nigeria. The study period 
spanned 99 months beginning October 1999. A data 
book was opened to accommodate the needed data. 
We included all patients referred to our unit through 
the clinics and the emergency rooms with suspicion 
of primary cancer of the lung. In the bio-data section, 
their ages and sexes were entered as they presented. 
The states of origin were also noted with smoking 
history, occupation, exposure to dust over time and 
history of premalignant lesions. The results of chest 
radiographs, computerised tomographic scans, 
sputum cytology, fine needle aspiration cytology, 
bronchoscopy, pleural biopsy, lung surgical specimens 
(open biopsy or resected lung biopsy) were noted for 
diagnosis. We adopted the old method of staging for 
uniformity because the research began in 1999. 
 The treatment modalities were recorded. Those 
that could not be offered surgery were referred 
appropriately to the oncology department after tissue 
diagnosis.
 The data were analysed to give various 
information. We sought correlation between smoking 
and occurrence of cancer (treating the males and 
females separately). For the purpose of regional 
identification of patients, we divided patients into 
three geopolitical zones (southwest, southeast 
and south-south zones) and we looked at regional 
disposition.
 We confirmed diagnosis in all cases before the 
patients were referred to oncology department. 
Only patients whose staging was concluded were 
included in the study. We excluded those whom for 
any reason(s) were not completely staged. Statistical 
analysis was done manually.
RESULTS
The research lasted 99 months beginning October 
1999 during which 267 patients were enlisted. They 
comprised of 148 males (55.4%) and 119 females 
(44.5%). The ages ranged from 37-76 years. A 
significant proportion of the patients (73.8%) were 
in the 50-69 year age range. The males constituted 
54.3% of the bulk while the females were 45.7% (table 
I). Stage IV patients were 183 (68.5%) while only 
three patients were found at stage I of disease. The 
histology showed squamous cell carcinoma in 27.7% 
of cases and adenocarcinoma in 64.0%. Among the 
stage IV group, 64.5% were adenocarcinoma while 
25.1% were squamous cell carcinoma.
Table 1 
Age and sex distribution
Age  Male Female     Total                  
30-39yrs 1 2     3(1.1%)     
40-49yrs 11 4    15(5.6%)     
50-59yrs 52 41  93(34.8%)
60-69yr  55  49           104(39.0%)      
>69  29  23  52(19.5%)     
 148(55.4%) 119(44.5%)   267(100.0%)
 Within the same group, 169 patients (92.3%) 
presented with pleural effusion. This constituted 
63.3% of the total number of patients studied. Only 
24 patients (9.0%) underwent bronchoscopy. Cytology 
specimens were collected in 191 patients and 89 
specimens (46.6%) were positive for malignancy. 
The remaining 102 cytology negative patients 
underwent needle biopsies (using Abram’s needle). 
We got 74 positive specimens. A further 21 patients 
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had open lung biopsies while the remaining seven 
patients had exploratory thoracotomy for diagnosis 
and treatment. Curative surgery was performed for 
13.1% while non curative surgery was performed for 
16.5%. Seventy nine patients underwent thoracotomy 
for lung resection. These were 46 lobectomies, six 
bi-lobectomies and 27 pneumonectomies. There 
was no segmentectomy or multi-segmentectomy. 
All the patients were referred to Oncologists for 
continuation of care. The correlation between smoking 
and malignancy was stronger among the male than 
within the female patients. We saw no significant 
relationship between malignancy and the region of 
origin of the patients.        
DISCUSSION 
There have been a lot of developments in the 
understanding of lung cancer aetiopathology and 
its management over the last decade. The causative 
roles of cigarette smoke have been further clarified 
as an initiator and promoter of carcinogenesis. 
Therefore, even without significant change in long 
term survival of lung cancer victims during the last 
decade, a significant improvement in cancer control 
has been obtained by biology-driven targeted therapy 
(1).  In the developing world, there is no properly 
conducted prospective research on long term survival 
of lung cancer patients. In fact little is known about 
the epidemiology and aetiopathogenesis of this 
very important malignancy. Therefore, there is a 
clear justification for this research which is about 
highlighting the aetiopathology of lung cancer and the 
challenges faced by practitioners in their management 
in the developing world. It is another channel, opened 
to compare notes with other international works in 
the field to determine the gap between what is ideal 
and what is obtainable in the developing world. 
 While applying the strict inclusion criteria for 
this research, we saw 267 patients in 99 months. They 
were 148 males and 119 females giving a M:F ratio of 
1.2:1 (Table 1). Unpublished experience at our centre 
showed increasing incidence of lung cancer among 
the female population. It has been difficult to show 
this trend statistically because there were no baseline 
figures.        
 Our youngest patient was 37 years and the oldest 
76 years. Stage IV disease was found in 68.5% of the 
patients. Within this group, 92.3% presented with 
pleural effusion. It therefore means that majority 
of the patients presented late. Only three patients 
reported with stage I disease. This challenge can only 
be mitigated by institution of proactive steps directed 
at routine screening of high risk patients.  It has been 
difficult to do a proper follow up on the patients 
because they were referred to oncologists after initial 
surgery and tissue diagnosis. This situation calls for 
awareness campaigns to educate the populace about 
the dangers inherent in smoking and the need for 
routine screening of smokers to detect lung cancers 
at early stage(s).   
 There was preponderance of adenocarcinoma 
in the series. Adenocarcinoma constituted 64.0% of 
cases seen while squamous cell carcinoma was found 
in 27.7% of them. 
 In Nigeria, there are six geopolitical zones 
with fairly different socio-cultural practices and 
environmental concerns. Three of these zones are in 
the south. The south – south and part of the south 
east are exposed to environmental pollution from oil 
exploration and mining. South-western people are 
exposed to agricultural dust and the cosmopolitan 
Lagos and Ibadan (both in the south west) are 
highly polluted with human wastes and vehicular 
hydrocarbons. 
 These three groups of people are reasonably 
represented in Lagos metropolis in good proportions. 
The only universal occurrence in the three groups was 
the strong correlation between prolonged smoking 
and malignancy especially among the males. The 
visibly increasing incidence amongst the females 
could not be totally explained by their smoking history 
alone. There are therefore certain (yet to be explained) 
predisposing factors that will require further studies 
to elucidate. 
 The main modalities of treatment included 
lung resections when the disease is operable, and 
chemotherapy and radiotherapy as adjuvant. There 
were 58 lobectomies (12 from bi-lobectomies) and 27 
pneumonectomies. Therefore, 79 patients (29.6%) were 
operable at presentation leaving 69.4% inoperable. 
No patient was suitable for segmentectomy at 
presentation. The situation can only be reversed 
through early presentation of cases. Patients and 
general practitioners need to be adequately informed 
about the need for early recognition and referral of 
Table 2
 Staging and Histology
   I   II   III   IV   Total 
Squamous  cell  1   10   17   46      74(27.7%)  
Adenocarcinoma  2   21   30   118      171(64.0%)        
Others     -   1   2   19      22(8.2%)                                      
 3(1.1%)  32(12.0%)  49(18.4%)  183(68.5%     267(100.0%)
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suspected lung cancer cases.
 More recently, it is believed that unprecedented 
and much more cost-effective results can be obtained 
when targeted agents are administered following 
appropriate biomarker–driven selection of non small 
cell lung cancer patients (8). The rapidly developing 
concept of translating biological development to 
medical therapy is expected to improve the outlook 
of primary lung cancers with time.
In conclusion, primary lung cancer might be affecting 
more females (and the males alike) and there is need to 
protect them from the known predisposing factors. We 
also believe that the developing world is dangerously 
lagging behind in acquisition and deployment of new 
diagnostic and therapeutic armamentaria for primary 
lung cancers. Practitioners in the developing world 
need to face this challenge by acquiring modern 
diagnostic and therapeutic equipment and drugs to 
better the lots of their patients.
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